Sun Pharma And Bayer announced that they have signed an agreement to market and distribute the second brand finerenone in India. Finerenone, a patented drug that reduces the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes mellitus. Indicated to reduce. The company said in a statement.
Under the agreement, Bayer has granted Sun Pharma non-exclusive rights to market and distribute another brand of fentanone under the brand. Livelssa, Fenrenone was first launched by Bayer in 2022 under the brand name Cerendia
Shweta RaiCountry Division Head of Bayer’s Pharmaceuticals business in South Asia said, “With the launch of the second brand of Fenrenone in India, through our partnership with Sun Pharma, we aim to make healthcare accessible to as many patients as possible. Taking forward Bayer’s commitment. The incidence of diabetes and its associated kidney and heart diseases is very high in India. The true value of innovations like finerenone can only be fully realized once they reach all eligible patients.
Kirti Ganorkar, CEO – India Business, Sun Pharma, said, “We are pleased to collaborate with Bayer to provide patients access to a new treatment that slows the progression of chronic kidney disease and prevents type-2 diabetes. Reduces the risk of associated kidney failure.”